The Filing Desk

Crescent Biopharma vs Evommune

Crescent Biopharma CBIO · Evommune EVMN · Pharmaceuticals

Evommune reported revenue of $13 million in fiscal 2025, 1.2 times Crescent Biopharma's $11 million in fiscal 2025. Crescent Biopharma had an operating margin of -1407.5%, against -623.6% at Evommune. Free cash flow was −$72 million at Crescent Biopharma and −$77 million at Evommune.

Side by side

Crescent BiopharmaEvommune
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$11M$13M
Revenue growth—85.7%
Revenue growth a year, last 5 years1.1%—
Gross margin——
Operating margin−1,407.5%−623.6%
Net margin−1,419.6%−529.8%
Free cash flow−$72M−$77M
Free cash flow margin−668.1%−589.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count—306.9%
Last close$12.91$7.24
P/E at the last close——
Insider trades, last 12 monthsbought $30.6 million, sold $1.5 millionbought $163,610, sold $2.3 million
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Crescent BiopharmaEvommune
Operating margin
Percent of revenue
Crescent BiopharmaEvommune
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Crescent BiopharmaEvommune

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Crescent Biopharma and Evommune pages.